MedTrace Logo

A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the Legs

NCT04401761 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3189

Last updated 2023-10-25

No results posted yet for this study

Summary

The study will focus on effectiveness and safety of rivaroxaban (Xarelto) when given together with acetylsalicylic acid (combination therapy) to patients suffering from coronary artery disease (a condition that affects the blood vessels supplying the heart) and / or peripheral artery disease (a condition that affects the blood vessels of the lower limbs) in the routine clinical practice. The study will help to collect data for prevention cardiovascular death, myocardial infarction (MI), stroke and major adverse limb events in adult patients. The study will focus on information on when and why physicians are starting to treat patients with combination therapy, treatment duration, reasons to discontinue treatment and previous therapies. The study will also investigate treatment outcomes for patients being treated with a combination therapy by their physicians.

Conditions

Interventions

DRUG

Rivaroxaban (BAY59-7939, Xarelto)

2.5 mg twice daily

DRUG

Acetylsalicylic acid

75 - 100 mg once daily at the discretion of the investigator

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-28
Primary Completion
2023-06-30
Completion
2023-09-29

Countries

  • Belgium
  • China
  • Colombia
  • Italy
  • Russia
  • Slovenia
  • South Korea
  • Spain
  • Switzerland
  • Taiwan

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04401761 on ClinicalTrials.gov